Health Economics›Burkitt lymphoma›Maintenance after upfront therapy

Maintenance after upfront therapy

Burkitt lymphoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COPAD/CYVE Variant #01	—	R 3 511	30d	—	—	~2	~R 7 021 indirect	—
COPADM Variant #01 Partial	—	R 1 546	—	—	—	~2	~R 3 093 indirect	—

2 of 2 regimens shown